TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05262595
Drug: NNC0471-0119 D
Normalized name: D
DrugBank: Rosomidnar (DB17154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months
Study: NCT05262595
Drug: Faster aspart
Normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faster aspart administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months
Study: NCT06291012
Drug: Quick response: Amoxicillin for 3 days
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of rapid response\*: Immediate stop of antibiotherapy (after 9 complete doses)~\*A rapid response is determined by a favorable clinical evolution (MASCOT 2002 study)
Study: NCT06291012
Drug: Delayed response: Amoxicillin for 5 days
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of delayed response: Continuation of antibiotic therapy for up to 5 days
Study: NCT06291012
Drug: Quick response: Amoxicillin for 5 days
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of rapid response\*: Continuation of antibiotherapy for up to 5 days~\*A rapid response is determined by a favorable clinical evolution (MASCOT 2002 study)
Study: NCT06291012
Drug: Delayed response: Amoxicillin for 7 days
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once the diagnosis of community-acquired alveolar pneumonia has been made, the investigator taking charge of the child writes a prescription for amoxicillin at a dosage of 80-100 mg/kg/day in 3 oral doses (morning, noon and evening), for a period of 4 days, before delivery of treatment to the family. The investigator will carry out a clinical re-evaluation on day 3 (D3), during which he will decide on the final duration of treatment.~In case of delayed response: Continuation of antibiotic therapy for up to 7 days
Study: NCT04651439
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injection of ZARZIO 30 MU/0,5mL and/or ZARZIO 48 MU/0,5mL, over a period of 5 consecutive days (1 injection per day during 30 minutes - - day 1 : set up standard treatment). The filgrastim solution will be diluted in 20 mL of 5% Glucose. The dose of ZARZIO administrated depends of the patient's weight :~* 20 to \< 30kg = 0,3 mL of ZARZIO 48 MU/0,5mL (subcutaneous route)~* 30 to \< 60kg = 0,5 mL of ZARZIO 30 MU/0,5mL (by IV)~* 60 to \< 90kg = 0,5 mL of ZARZIO 48 MU/0,5mL (by IV)~* 90 to \< 120kg = 2x0,5 mL of ZARZIO 30 MU/0,5mL (by IV)~* 120 to 150kg = 0,5 mL of ZARZIO 30 MU/0,5mL + 0,5 mL of ZARZIO 48 MU/0,5mL (by IV)~* \> 150kg = 2x0,5 mL of ZARZIO 48 MU/0,5mL (by IV)
Study: NCT05040971
Drug: Semaglutide 2.4 mg
Normalized name: semaglutide 2.4 MG in 0.75 ML Auto-Injector
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered subcutaneously (s.c., under the skin) once weekly as well as reduced-calorie diet and increased physical activity for 52 weeks. Doses gradually increased to 2.4 mg
Study: NCT06086704
Drug: 18F-fluorofuranylnorprogesterone
Normalized name: 18F-fluorofuranylnorprogesterone
DrugBank: Fluorofuranylnorprogesterone F-18 (DB15282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-FFNP will be given by a slow infusion (approximately 2 minutes), and the dose administered will be approximately 7 mCi.
Study: NCT06086704
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hormone based chemotherapy that reduces estrogen, 1 mg anastrozole once daily by mouth for a minimum of 14 days
Study: NCT06086704
Drug: FDA-approved gadolinium-based intravenous contrast agent
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA-approved gadolinium-based intravenous contrast agent used for the MRI portion of this study
Study: NCT05111431
Drug: Dexmedetomidine Hydrochloride Nasal Spray
Normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the low weight group, the subjects will receive a low dose of dexmedetomidine nasal spray.~In the high weight group, the subjects will receive a high dose of dexmedetomidine nasal spray.
Study: NCT05111431
Drug: Dexmedetomidine hydrochloride nasal spray blank preparation
Normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the low weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.~In the high weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.
Study: NCT03153280
Drug: Lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose escalation of Lithium to determine the maximum tolerated dose (MTD)
Study: NCT05688202
Drug: Lidocaine/Prilocaine 2.5%-2.5% Topical Application Cream
Normalized name: Lidocaine/Prilocaine 2.5%-2.5% Topical application Cream
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative, lidocaine 2.5% and prilocaine 2.5% cream (EMLA 5%, eutectic mixture of local anesthetic; AstraZeneca LP, Wilmington, DE, USA) is applied under occlusion for 60 minutes prior to the removal of local anesthetics
Study: NCT05688202
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 500 mg paracetamol-based oral analgesic (Efferalgan, Upsa SAS, France) is administered right before the procedure.
Study: NCT05688202
Drug: Lidocaine 2% Injectable Solution
Normalized name: lidocaine 2% injectable solution
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The operation sites are sterilized with alcohol pads and injected intradermally with a solution of 2% lidocaine.
Study: NCT03153280
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose as used in standard of care - 130 mg/m2.
Study: NCT05171309
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg once daily (QD) oral dosing.
Study: NCT05171309
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg intravenously every 2 weeks.
Study: NCT05171309
Drug: NK cell
Normalized name: NK Cells
DrugBank: IL15-NK Cell (DB15725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cord blood derived NK cells 4 cycles, one cycle is defined as: total cells ≥1×109 per time, continuous intravenous infusion for 2 days every 14±2 days
Study: NCT04772352
Drug: febuxostat treatment
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: According to NAFLD guidelines, participants accept febuxostat treatment (40mg, once a day, orally)
Study: NCT05072860
Drug: Topical tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
Study: NCT05558137
Drug: Mivacurium
Normalized name: Mivacurium
DrugBank: Mivacurium (DB01226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2 mg/kg based on ideal body weight calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower
Study: NCT00002028
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05182658
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The proposed intervention will be administration of empagliflozin at a standard dose of 10 mg daily for a period of 12 months. Patients with diagnosed diabetes will be excluded from the study. Patients (n = 250) will be randomized in a double-blind fashion to empagliflozin or placebo group.
Study: NCT06523764
Drug: tegoprazan
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tegoprazan 50 mg and minocycline 100 mg by mouth, twice daily for 14 days
Study: NCT06523764
Drug: bismuth potassium citrate
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
Study: NCT06523764
Drug: Esomeprazole 40mg
Normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
Study: NCT06523764
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bismuth potassium citrate 240 mg,esomeprazole 40 mg, amoxicillin 1000mg, and clarithromycin 500 mg by mouth,twice daily for 14 days
Study: NCT06284590
Drug: L19IL2
Normalized name: L19IL2
DrugBank: Darleukin (DB17157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1: The amount of L19IL2 that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 13 MioIU/1 mL of L19IL2.
Study: NCT06284590
Drug: L19TNF
Normalized name: Daromun component l19tnf
DrugBank: Onfekafusp alfa (DB16269)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 2: The amount of L19TNF that is intratumorally administered into injectable cutaneous, subcutaneous, and nodal tumors once weekly for up to 4 weeks is dependent on the size of the tumor. The maximum dose to be administered in a single treatment visit is 400 μg/1 mL of L19TNF.
Study: NCT05171374
Drug: Dabrafenib
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Observational stusy. No intervention is planned
Study: NCT05171374
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Observational stusy. No intervention is planned
Study: NCT06089733
Drug: Part A ABSK201 and Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive a single 10mg Oral administration of ABSK021 at C1D1, followed by a washout period of at least 14 days. The second cycle (C2): after the end of the first cycle, the subjects will receive 200 mg of C2D1-C2D24 Itraconazole oral liquid and a single 10 mg of ABSK021 Oral administration at C2D4.
Study: NCT06089733
Drug: Part A ABSK201 and Rifampicin
Normalized name: rifampicin and isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive a single dose of 50 mg of ABSK021 Oral administration once at C1D1, followed by a washout period of at least 14 days. Subjects will receive 600 mg of Rifampicin capsules once a day at C2D1-C2D15 and a single dose of ABSK021 Oral administration at C2D7, with the dose of 50 mg.
Study: NCT04607434
Drug: Ocotillol Type Ginsenoside Derivatives
Normalized name: ginsenoside
DrugBank: Ginsenosides (DB14152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral blood PMN of patients with ARDS were taken. The neutrophils isolated from peripheral blood of ARDS patients were incubated with different doses of OCT glycine derivatives (20,50,100 UM) for 20 h
Study: NCT05372692
Drug: mesothelin-specific chimeric antigen receptor T cell injection
Normalized name: Autologous T cells transduced with retroviral vector encoding an anti-CD-19 CD28/CD3-zeta chimeric antigen receptor
DrugBank: Axicabtagene ciloleucel (DB13915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous T cell injection
Study: NCT05949190
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg dose
Study: NCT05949190
Drug: Sulfadoxine pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monthly, 1,500/75mg dose
Study: NCT06417099
Drug: Dihydroartemisinin
Normalized name: Dihydroartemisinin
DrugBank: Artenimol (DB11638)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: dihydroartemisinin 40mg tid po for 90 consecutive days
Study: NCT05263700
Drug: 68Ga-FAPi-46
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAPI-46 is a small molecular radiopharmaceutical that binds to the fibroblast activated protein on cancer associated fibroblasts. Gallium-68 (68Ga) is a positron-emitting isotope with a half-life of 68 minutes.
Study: NCT06343064
Drug: Vebreltinib
Normalized name: Vebreltinib
DrugBank: Vebreltinib (DB16823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase Ib is a dose escalation study, the initial dose of Vebreltinib is 100mg/150mg/200mg,according to the result of Phase Ib, will confirm the RP2D.
Study: NCT02437019
Drug: PCI-32765 (Ibrutinib)
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive PCI-32765 (ibrutinib) 420 mg (three 140-mg capsules) oral once daily continuously on a 28-day cycle.
Study: NCT00001086
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001086
Drug: Abacavir sulfate
Normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00001086
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06546254
Drug: Lidocaine 1% Injectable Solution
Normalized name: lidocaine 1% injectable solution
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 cc 1% lidocaine paracervical injection
Study: NCT06546254
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 cc normal saline paracervical injection
Study: NCT04731298
Drug: Emapalumab
Normalized name: Emapalumab
DrugBank: Emapalumab (DB14724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emapalumab is a fully human immunoglobulin G1 (IgG1) anti-IFNγ monoclonal antibody that binds to and neutralizes IFNγ. Emapalumab binds to both soluble and receptor (IFNγR1)-bound forms of IFNγ.~Emapalumab is in development for treatment of primary and secondary HLH. The benefit expected from the targeted neutralization of IFNγ by emapalumab has been validated by the recent FDA approval of emapalumab for treatment of patients with pHLH who have refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. The safety profile has been assessed as acceptable.~Emapalumab will be administered by intravenous infusion over 1 to 2 hours, depending on the volume of the infusion. The first infusion must be performed within 12 hours after CXCL9 levels have been measured above defined threshold. Treatment will last until maximum dose 15 (up to 56 days) or until evidence of engraftment, whichever comes first.
Study: NCT06274996
Drug: Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Upadacitinib, a selective Janus kinase (JAK) inhibitor taken orally, is being assessed for its unique capacity to attenuate inflammatory pathways in IBD at a cellular level by selectively inhibiting JAK1, a pathway integral to inflammatory cytokine production. This study focuses on its use as monotherapy for Chinese patients unresponsive to conventional IBD treatments, such as aminosalicylates and corticosteroids. By centering on a demographic typically underrepresented in research, the study aims to provide new insights into dosing, treatment frequency, and duration, thus enhancing the understanding of Upadacitinib\&#39;s safety and efficacy. The retrospective analysis of patient data is anticipated to inform more personalized treatment approaches, potentially improving IBD management and patient quality of life.
Study: NCT05634785
Drug: Cyclophosphamid
Normalized name: Cyclophosphamid
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two to 14 days prior to the initial ATLCAR.CD30 infusion, subjects will receive a lymphodepletion regimen that includes 300 mg per square meter of intravenous cyclophosphamide.
Study: NCT05634785
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two to 14 days prior to the initial ATLCAR.CD30 infusion, subjects will receive a lymphodepletion regimen that includes daily 30 mg per square meter of intravenous fludarabine infusion for 3 days.
Study: NCT06651268
Drug: while Group B (vancomycin group, n=12) had vancomycin powder applied during closure. T
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: while Group B (vancomycin group, n=12) had vancomycin powder applied during closure. T
Study: NCT06429696
Drug: PD-L1 inhibitor combined with apatinib
Normalized name: PD-L1/4-1BB bispecific antibody
DrugBank: ATG-101 (DB17162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every 3 weeks (21 days) is a treatment cycle. After 4-6 cycles of induction therapy, patients whose efficacy is evaluated as CR, PR or SD (according to RECIST 1.1) will enter maintenance therapy until the disease progresses and becomes intolerable. Toxic and side effects, death, withdrawal of information or the investigator's decision to withdraw the subject from the study, non-compliance with study treatment or other reasons specified in the study procedures or protocol, or treatment for up to 2 years. Maintenance treatment: PD-L1 inhibitor + apatinib 250 mg po qd, maintained for up to 2 years. Note: The specific PD-L1 inhibitor is selected by the researcher, such as adebelimab 1200mg iv, q3w; or atezolizumab 1200mg iv d1, q3w; or durvalumab 1500mg iv d1, q3w . The selection of PD-L1 inhibitors in the maintenance phase is consistent with the first-line standard treatment in the induction phase.
Study: NCT04818216
Drug: Nicotinamide riboside
Normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg Nicotinamide riboside capsules
Study: NCT05707442
Drug: Acetazolamide-based medical therapy
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade \<1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily.
Study: NCT06499415
Drug: 5FU-Calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical 5FU-CAL, twice daily, during 4 or 6 consecutive days, depending on the treatment location
Study: NCT05868265
Drug: Enfortumab Vedotin
Normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will receive enfortumab vedotin at 1.25 mg/kg on days 1 and 8 of 21 days cycle, for a total of three cycles.
Study: NCT05210582
Drug: Afamelanotide
Normalized name: Afamelanotide
DrugBank: Afamelanotide (DB04931)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive afamelanotide over a three-month period, with an additional three-month follow up.
Study: NCT05935657
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.075 mg/kg Remimazolam bolus infusion for 1 min, then 0.1\~1.0 mg/kg/h continuous infusion
Study: NCT05935657
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mcg/kg Dexmedetomidine infusion for 10 min, then 0.2\~0.7 mcg/kg/h continuous infusion
Study: NCT05524857
Drug: Fedratinib Oral Capsule 300 mg
Normalized name: fedratinib Oral Capsule
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 300 mg by mouth, once daily
Study: NCT05524857
Drug: Decitabine 20 mg/m2
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/m2 for injection, for intravenous use
Study: NCT05524857
Drug: Fedratinib Oral Capsule 400 mg
Normalized name: fedratinib Oral Capsule
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 400 mg by mouth, once daily
Study: NCT05733234
Drug: Mechanical Treatment
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dental instrument is used in combination with Chlorhexidine to decontaminate the implant surface
Study: NCT06054152
Drug: PD-1 inhibitor based immunotherapy
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received at least 4 cycles of PD-1 inhibitor-based immune monotherapy or chemoimmunotherapy. PD-1 drug selection should be limited in 4 types of PD-1 inhibitor approved by China FDA and launched in China and Opdivo or Keytruda.
Study: NCT05980871
Drug: Ceftriaxone
Normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone (1g intramuscularly once)